The EED Knockout Raji Polyclonal Cells represent a polyclonal population of Raji cells engineered via CRISPR/Cas9-mediated disruption of the EED gene locus. This polyclonal knockout product provides a heterogeneous loss-of-function model that disrupts the core component of the Polycomb Repressive Complex 2 (PRC2). The cells are supplied as a mixed population, reflecting a range of editing events without selection for clonal homogeneity, and are suitable for studying the immediate consequences of EED ablation in a B-lymphocyte background.
The host cell line, Raji, is an immortalized human B lymphocyte derived from a Burkitt lymphoma patient. These cells are Epstein-Barr virus (EBV)-positive and exhibit a lymphoblastoid phenotype with characteristic surface markers such as CD19, CD20, and CD22. Raji cells are widely utilized as a model system for B-cell malignancies, humoral immunity, and lymphomagenesis, offering a relevant cellular context for dissecting epigenetic mechanisms that govern B-cell proliferation, differentiation, and transformation.
EED functions as an indispensable scaffolding subunit of PRC2, recognizing trimethylated lysine 27 on histone H3 (H3K27me3) and allosterically activating the methyltransferase activity of EZH2. Through this interaction, EED sustains the propagation of H3K27me3 marks, leading to transcriptional repression of numerous developmental and tumor suppressor genes. EED operates within a network involving PRC2 core components EZH2, SUZ12, and RBBP4/7, as well as accessory factors such as JARID2, AEBP2, and PCL proteins, which modulate complex recruitment and activity. Upstream signals including non-coding RNA HOTAIR and AKT-mediated phosphorylation converge on PRC2, while downstream targets encompass HOX gene clusters, the CDKN2A locus (encoding p16INK4a and p14ARF), and E-cadherin (CDH1), among others.
In Raji cells, the targeted disruption of EED results in the loss of PRC2 integrity and a consequent global reduction in H3K27me3 levels, as validated by mechanistic studies. This derepresses PRC2 target genes, potentially restoring expression of tumor suppressors and lineage-specifying factors that are abnormally silenced in Burkitt lymphoma. The model is therefore instrumental for elucidating how PRC2-mediated gene silencing contributes to B-cell oncogenesis, as well as for assessing the epigenetic vulnerabilities of lymphoma cells. Given the relevance of EED to Weaver syndrome and overgrowth syndromes, this polyclonal knockout also allows comparative studies of developmental gene regulation.
Researchers may employ the EED Knockout Raji Polyclonal Cells to investigate epigenetic mechanisms underlying B-cell malignancies, screen small-molecule inhibitors targeting the EED?CEZH2 interaction or PRC2 activity, and perform genome-wide analyses such as ChIP-seq for H3K27me3 and RNA-seq to map transcriptional changes. Additional applications include Western blotting for PRC2 components, RT-qPCR validation of target gene expression (e.g., p16, HOX genes), proliferation and viability assays, flow cytometric immunophenotyping, and drug sensitivity profiling with PRC2 inhibitors. For further details on protocol optimization or custom applications, please contact Ascent Research.
